Lupin Ltd is known for upholding strong values and a robust corporate philosophy. Guided by their core principles, Lupin strives for excellence, integrity, and transparency in all their operations. The company firmly believes in providing high-quality pharmaceutical products that improve the lives of patients globally. With a focus on innovation, Lupin continually invests in research and development to bring cutting-edge healthcare solutions to the market. Dedicated to social responsibility, Lupin actively engages in initiatives for the betterment of society, promoting sustainable development and fostering inclusive growth. Through their unwavering commitment to quality, ethics, and social welfare, Lupin Ltd emerges as an industry leader, delivering value to various stakeholders and ensuring a positive impact on the healthcare sector.

Lupin Ltd, a renowned pharmaceutical company, has a significant global presence. The company primarily operates in various countries and regions, including but not limited to India, United States, Europe, Japan, and South Africa. With its strong foothold in these markets, Lupin Ltd has established itself as a leading player in the pharmaceutical industry.

Lupin Ltd has accomplished several significant milestones throughout its history. One of the major achievements was the company's successful listing on the Bombay Stock Exchange and the National Stock Exchange of India. Lupin also made notable achievements in the global pharmaceutical industry by receiving various regulatory approvals for its high-quality and affordable generic medications. Furthermore, Lupin has expanded its operations globally by establishing a strong presence in key markets like the United States, Europe, Japan, and other emerging markets. These achievements have reinforced Lupin's position as a leading global pharmaceutical company, delivering innovative healthcare solutions to patients worldwide.

Lupin Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1968, Lupin has emerged as a global leader in the pharmaceutical industry. The company's relentless focus on innovation and research has paved the way for groundbreaking drug discoveries and cutting-edge formulations. Lupin operates through various business segments, catering to a wide range of therapeutic areas including cardiovascular, respiratory, central nervous system, and anti-infective. With a strong global presence across multiple countries, Lupin has earned a stellar reputation for delivering affordable and high-quality healthcare solutions. Over the years, Lupin Ltd. has consistently showcased its commitment to improving global health outcomes with its diverse portfolio of pharmaceutical products.

The main competitors of Lupin Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd., and Torrent Pharmaceuticals Ltd.

Lupin Ltd is primarily active in the pharmaceutical industry.

The business model of Lupin Ltd revolves around the pharmaceutical industry. As a leading global pharmaceutical company, Lupin focuses on developing, manufacturing, and marketing a diverse range of generic and branded pharmaceutical products. With a strong emphasis on research and development, Lupin strives to bring innovative solutions and affordable medications to patients worldwide. The company's business model includes a global presence, strategic partnerships, and a commitment to quality and compliance. Lupin Ltd's extensive product portfolio covers various therapeutic areas, including cardiovascular, central nervous system, dermatology, and respiratory, among others, catering to the healthcare needs of millions of people.

The Lupin P/E ratio is 48.14.

The Lupin P/S ratio is 4.61.

The Quality Investing for Lupin is 6/10.

The Lupin revenue is 200.11 B INR.

The Lupin profit is 19.14 B INR.

Lupin Ltd is a leading pharmaceutical company based in India. The company's business model is based on the production and distribution of pharmaceutical products and generic medications worldwide. Lupin operates in three business segments: generics, branded products, and carbamazepine. The generics segment is the core of Lupin's business model, offering a wide range of cost-effective alternatives to expensive brand-name medications. Lupin also produces branded products, primarily sold in India, including antibiotics, diabetes medications, and hormonal treatments. The carbamazepine segment specializes in the production of antiepileptic drugs and is a significant part of Lupin's business model. The company also emphasizes research and development, investing a significant percentage of its revenue in the development of new drugs. Lupin has established a global distribution network, with subsidiaries in the US, Europe, and Japan, as well as distribution partners in other countries. The company has made strategic acquisitions and mergers to strengthen its presence in different regions, such as the acquisition of Gavis in 2016 to expand its generics business in the US. Overall, Lupin's business model revolves around the production and distribution of pharmaceutical products and generics worldwide, with a strong emphasis on research and development and a global distribution network.

Lupin pays a dividend of 4 INR distributed over payouts per year.

The dividend cannot currently be calculated for Lupin or the company does not pay out a dividend.

The ISIN of Lupin is INE326A01037.

The ticker of Lupin is LUPIN.NS.

Over the past 12 months, Lupin paid a dividend of 8 INR . This corresponds to a dividend yield of about 0.4 %. For the coming 12 months, Lupin is expected to pay a dividend of 7.37 INR.

The current dividend yield of Lupin is 0.4 %.

Lupin pays a quarterly dividend. This is distributed in the months of August, August, August, August.

Lupin paid dividends every year for the past 23 years.

For the upcoming 12 months, dividends amounting to 7.37 INR are expected. This corresponds to a dividend yield of 0.37 %.

Lupin is assigned to the 'Health' sector.

To receive the latest dividend of Lupin from 9/1/2024 amounting to 8 INR, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

The last dividend was paid out on 9/1/2024.

In the year 2023, Lupin distributed 4 INR as dividends.

The dividends of Lupin are distributed in INR.